שווי כולל של החברה: ArriVent Corp (AVBP)

The market price of ArriVent BioPharma, Inc (AVBP), as confirmed by the chart, underscores the risks associated with potential regulatory rejection or the emergence of stronger competitors, with the company's Enterprise Value standing at 386.57. The company's current stability relies on post-IPO proceeds and volunteer recruitment rates. Growth prospects are based on the success of furmonertinib in treating NSCLC, the anticipation of Breakthrough Therapy designation, and a potential buyout by industry behemoths.

Enterprise value is calculated as the sum of market capitalization and net debt. This metric determines the actual cost of a full business buyout, excluding the impact of existing cash reserves. For ArriVent BioPharma, Inc (AVBP), this figure reflects the investment attractiveness of its lung cancer therapy development. The efficacy of the drug furmonertinib directly impacts the asset valuation. By analyzing fluctuations in enterprise value, an investor assesses the company's fair price.